Literatur
Vorbeugende Impfung gegen HPV
- Ault KA et al (2007): Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369 (9576):1861-8
- Block SL et al (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (5): 2135-2145
- Bundeszentrale für gesundheitliche Aufklärung (2006) Jugendsexualität. Repräsentative Wiederholungsbefragung von 14- bis 17-Jährigen und ihren Eltern. http://www.sexualaufklaerung.de/cgi-sub/fetch.php?id=473
- European Public Assessment Report Cervarix
- http://www.emea.europa.eu/humandocs/PDFs/EPAR/cervarix/H-721-de1.pdf
- European Public Assessment Report Gardasil http://www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/070306de1.pdf
- Fairley CK et al (2009): Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.Sex Transm Infect 2009 Dec;85(7):499-502. Epub 2009 Oct 16.
- Garland SM et al (2007): Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM 356(19):1928-43
- Gross G (2006) HPV-Vakzine: Wer sollte wann, wo und wie geimpft werden? Deutsches Ärzteblatt 103, 15.12.2006 http://www.aerzteblatt.de/v4/archiv/artikel.asp?id=53861
- Harper D et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomised control trial. Lancet Vol 367 (9518): 1247-55
- Hildesheim A et al for the Costa Rican HPV Vaccine Trial Group (2007) Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial. JAMA 298(7):743-753
- Hoyer H et al (2005) Cumulative 5-year diagnoses of CIN 2, CIN 3 or cervical cancer after concurrent high-risk HPV and cytology testing in primary screening setting. Int J Cancer 116: 136-143
- Koutsky L et al (2006) Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 24 S3:114-121
- Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. J. Clin Invest 116: 1167-73
- Mao C et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (1): 18-27
- Olsson SE et al (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-39
- Paavonen J et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-70
- Poland GA et al (2005) Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical trial. Mayo Clin Proc 80(5):601-10
- Robert Koch Institut (2007) Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiologische Bulletin 12: 97-103. http://www.rki.de/cln_048/nn_196658/DE/Content/Infekt/EpidBull/Archiv/2007/12__07,templateId=raw,property=publicationFile.pdf/12_07.pdf
- Saslow D et al (2007) American Cancer Society Guideline for HPV vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57: 7-28
- The Future II Group (2007) Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med 356:1915-27
- Villa LL et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicente phase II efficacy trial. Lancet Oncol 6: 271-8
- Villa LL et al (2006) High sustained efficacy of a prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) (L1 Virus-Like Particle (VLP) Vaccine through 5 years of follow up. Br J Cancer 95 (11): 1459-66
- Winer RL et al (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (3): 218-226